The first cohort at the University College London Hospital (UCLH) cohort was composed of 22 patients with a different degree of hematological disorders (from CH to MDS) that only carry mutations in the TET2 gene (Table S7). This evidence concerns the gene TET2 and myelodysplastic syndrome.